ID: ALA5274157

Max Phase: Preclinical

Molecular Formula: C20H18N6O4S2

Molecular Weight: 470.54

Associated Items:

Representations

Canonical SMILES:  CSc1nn(-c2ccc(S(C)(=O)=O)cc2)c2ncnc(NCC(=O)/N=C/c3ccco3)c12

Standard InChI:  InChI=1S/C20H18N6O4S2/c1-31-20-17-18(22-11-16(27)21-10-14-4-3-9-30-14)23-12-24-19(17)26(25-20)13-5-7-15(8-6-13)32(2,28)29/h3-10,12H,11H2,1-2H3,(H,22,23,24)/b21-10+

Standard InChI Key:  HZBQXGCHSPQWBZ-UFFVCSGVSA-N

Associated Targets(Human)

Cyclooxygenase-2 13999 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Cyclooxygenase-1 5266 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Rattus norvegicus 775804 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 470.54Molecular Weight (Monoisotopic): 470.0831AlogP: 2.59#Rotatable Bonds: 7
Polar Surface Area: 132.34Molecular Species: NEUTRALHBA: 10HBD: 1
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 0.12CX LogP: 1.65CX LogD: 1.65
Aromatic Rings: 4Heavy Atoms: 32QED Weighted: 0.32Np Likeness Score: -1.75

References

1. Sharma S, Kumar D, Singh G, Monga V, Kumar B..  (2020)  Recent advancements in the development of heterocyclic anti-inflammatory agents.,  200  [PMID:32485533] [10.1016/j.ejmech.2020.112438]

Source